ArticleUpdates in surgery2026
Routine pathological nodal status evaluation significantly modifies 2025 ATA risk category of patients with unifocal cN0 cT1b-T2 PTC eligible for thyroid lobectomy: results from a multicentre international study.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult lymph node metastases occur in up to 50% of patients with clinically node-negative papillary thyroid carcinoma eligible for thyroid lobectomy. Nevertheless, the 2025-ATA guidelines discourage routine prophylactic ipsilateral central neck dissection in clinically node-negative clinical T1b-T2 low-risk disease. This multicentric retrospective study evaluated the impact of routine ipsilateral central neck dissection on recurrence risk stratification in patients with unifocal clinically node-negative clinical T1b-T2 papillary thyroid carcinoma eligible for thyroid lobectomy. Among 9,028 thyroidectomies performed in four referral centres, 264 patients met the inclusion criteria. Lymph node metastases were found in 135 (51.1%) patients, with extranodal extension in 8.9% of node-positive cases. Median tumour size was 12 mm. Final histopathology showed pT1a disease in 88 (33.3%), pT1b in 165 (62.5%), and pT2 in 11 (4.2%). Extrathyroidal extension, vascular invasion, multifocality, and aggressive histologic variants were observed in 12.1, 60.6, 43.2, and 18.9%, respectively. According to the 2025-ATA risk stratification system, excluding pathologic nodal status, 60 (22.7%) patients were low risk, 31 (11.8%) low-intermediate risk, 170 (64.4%) intermediate-high risk, and 3 (1.1%) high risk. After inclusion of nodal status, 54 (20.4%) were low risk, 24 (9.1%) low-intermediate risk, 171 (64.8%) intermediate-high risk, and 15 (5.7%) high risk (p < 0.001). Overall, 8% of patients experienced risk upgrading, and > 70% were classified in higher-risk categories. Pathologic nodal assessment substantially modifies recurrence risk stratification in clinical node-negative T1b-T2 papillary thyroid carcinoma eligible for thyroid lobectomy, supporting routine ipsilateral central neck dissection for staging and tailored surgical decision-making.
Indexed as
Identifiers
42479126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.